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CD1-restricted T lymphocytes recognize lipid 
antigens presented by the nonpolymorphic, 
MHC class I–related family of CD1 molecules 
(Porcelli and Modlin, 1999). CD1-restricted 
T cells can respond to lipid antigens derived from 
microbial cells and may exert protective roles 
during host infection (Moody et al., 2000, 2004; 
Amprey et al., 2004; Gilleron et al., 2004; Kinjo 
et al., 2005; Sriram et al., 2005; Wu et al., 2005; 
Montamat-Sicotte et al., 2011). A striking char-
acteristic of many CD1-restricted T cells is auto-
reactivity against different types of APCs even 
in the absence of microbial antigens, implying 
that they can also recognize endogenous self-lipid 
molecules (Dellabona et al., 1993; Mattner 
et al., 2005; Vincent et al., 2005). Autoreactive 
T cells recognize different types of self-lipids 
present in cell membranes and synthesized within 
different cellular compartments (Shamshiev 
et al., 1999, 2000; Gumperz et al., 2000; Wu 
et al., 2003; De Libero et al., 2005). CD1a- and 
CD1c-autoreactive T cells are relatively abun-
dant among circulating T cells in healthy indi-
viduals (de Jong et al., 2010; de Lalla et al., 2011) 
and might become activated by host antigens in 
autoimmune diseases and cancer. Lipid-specific 
T cells can control cancer cell growth in mouse 
models (Berzofsky and Terabe, 2009) as well as 
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T cells that recognize self-lipids presented by CD1c are frequent in the peripheral blood of 
healthy individuals and kill transformed hematopoietic cells, but little is known about their 
antigen specificity and potential antileukemia effects. We report that CD1c self-reactive  
T cells recognize a novel class of self-lipids, identified as methyl-lysophosphatidic acids 
(mLPAs), which are accumulated in leukemia cells. Primary acute myeloid and B cell acute 
leukemia blasts express CD1 molecules. mLPA-specific T cells efficiently kill CD1c+ acute 
leukemia cells, poorly recognize nontransformed CD1c-expressing cells, and protect immuno-
deficient mice against CD1c+ human leukemia cells. The identification of immunogenic self-
lipid antigens accumulated in leukemia cells and the observed leukemia control by 
lipid-specific T cells in vivo provide a new conceptual framework for leukemia immune 
surveillance and possible immunotherapy.
© 2014 Lepore et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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in human patients (Dhodapkar and Richter, 2011; Metelitsa, 
2011), but it remains unknown whether they recognize unique 
lipids expressed by tumor cells.
Acute leukemia comprises a heterogeneous group of he-
matological disorders characterized by blood and bone mar-
row accumulation of immature and abnormal cells derived 
from hematopoietic precursors (Pui et al., 2004; Rubnitz 
et al., 2008). Current therapy for acute leukemia is based on 
polychemotherapy and allogeneic hematopoietic stem cell 
(HSC) transplantation (HSCT). A major cause of treatment 
failure and area of substantial unmet need in HSCT is post-
transplant regrowth of residual leukemia blasts that survive 
the conditioning regimen (Wingard et al., 2011). Donor- 
derived T cells transferred into patients may induce a benefi-
cial graft versus leukemia (GVL) reaction capable of maintaining 
remission (Kolb, 2008), but grafted T cells are also capable of 
killing patient cells in nonhematopoietic tissues to induce 
detrimental graft versus host disease (GVHD; Socié and Blazar, 
2009). A promising therapeutic strategy is the selective tar-
geting of T cell responses against malignant hematopoietic 
cells, while maintaining hematopoietic capacity among grafted 
cells and preserving organ functions in recipient patients 
(Kolb, 2008). Because CD1 molecules are both nonpolymor-
phic and preferentially expressed by mature hematopoietic 
cells (Porcelli and Modlin, 1999; Brigl and Brenner, 2004), tar-
geting tumor-associated lipid antigens presented by CD1 
molecules might provide opportunities to improve the effi-
cacy of HSCT. Immune recognition of tumor-associated lipid 
antigens may also complement ongoing antitumor responses 
mediated by protein antigens.
Here we have identified the novel self-lipid antigen that 
stimulates CD1c autoreactive T cells to destroy tumor cell 
lines and primary human leukemia cells. We report that both 
group 1 CD1 molecules and a novel class of tumor-associated 
lipids are broadly expressed by different types of acute leuke-
mia. In addition to killing CD1c+ leukemia cell lines and pri-
mary blasts in vitro, the CD1c-restricted T cells also displayed 
therapeutic efficacy in a mouse xenograft model of human 
leukemia. Our findings provide proof-of-concept evidence 
that T cell responses against lipids accumulated in acute leu-
kemia could be exploited for leukemia immunotherapy.
RESULTS
Identification of CD1c-presented antigenic  
lipids in leukemia cells
Autoreactive T cells restricted to CD1c are abundant in the 
peripheral blood of healthy donors (de Lalla et al., 2011) and 
Figure 1. Recognition of leukemia cell lines and leukemia-derived 
lipids by CD1c autoreactive T cells. (A) Flow cytometry detection of 
CD1c surface protein in C1R and THP1 cell lines transfected with CD1c 
cDNA and other leukemia cell lines constitutively expressing CD1c. Gray 
histograms represent staining with isotype-matched control mAbs. (B) Rec-
ognition of CD1c-expressing leukemia cell lines by CD1c self-reactive  
T cell clones DN4.99 (left) and K34A27f (right) at the indicated E/T ratios.  
T cell activation was assessed by measurements of GM-CSF release. (C) Anti-
CD1c blocking mAbs (-CD1c) inhibit the recognition of CD1c-expressing 
leukemia cell lines by DN4.99 (left) and K34A27f (right). T cell reactivity in 
the absence of antibodies (no Abs) and presence of matched isotype con-
trol mAbs (ctrl) is shown. T cell activation was evaluated my measuring 
GM-CSF release. (D) Fractions (A–J) of THP1 lipids extracted from the 
organic (left) and aqueous phase (right) were used to stimulate DN4.99  
T cells in the presence of fixed THP1-CD1c cells. T cell activation was as-
sessed by measurement of GM-CSF release and expressed as fold change 
over background. (E) CD1c self-reactive T cell clones DN4.99 (left) and 
K34A27f (middle) or CD1c-restricted M. tuberculosis–specific DL15A31  
T cells (right) were cultured either alone (T cells) or in the presence of 
plastic-bound sCD1c molecules loaded with sulfatide, fraction G from 
aqueous extraction (G), or M. tuberculosis sonicate (MTB) with or without 
anti-CD1c blocking mAbs (-CD1c). T cell activation was assessed by 
measurement of GM-CSF release. All data are represented as mean ± SD. 
Results are representative of three (B, C, and E) and seven (D) independent 
experiments. **, P < 0.01; ***, P < 0.001, determined by two-tailed Student’s 
t test. P-values in C refer to both groups “no Abs” and “ctrl” individually 
compared with the group “-CD1c.”
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(m/z 14). Based on these data, we assigned a methylated phos-
phate head to the structure of the antigenic lipid.
We next used positive ion mode analyses to confirm the 
candidate structure proposed by the negative ion mode data. 
The protonated ion of the novel compound (m/z 411) gener-
ated a fragment of m/z 299 and associated loss of 112 D in 
mass, corresponding to the loss of a methyl hydrogen phos-
phate moiety (Fig. 2 F). Ions with m/z of 169 and 187 were 
detected in the low mass region (Fig. 2 F), consistent with the 
presence of a 14-D methylated head group bound to phospho-
lipids of 155 or 173 D (Fig. 2 G). Additional experiments were 
then performed using a triple quadrupole analyzer to confirm 
the presence of a phospho-methyl group within the novel lipid 
antigen. Upon collision-induced dissociation, the deprotonated 
ion of m/z 409 generated ions of m/z 377 and 111 (not de-
picted). An excess mass of 14 D again pointed to the presence 
of a methylated phosphate group (m/z 97 + 14).
To elucidate the structure of the hydrophobic chain of the 
novel lipid antigen, we used triple-stage MS (MS3) in negative 
mode with an ion-trap instrument. Fragmentation of ion m/z 
377 generated a further ion of m/z 239 (Fig. 2 H), indicative 
of an ether-bonded C16 alkyl or alkenyl chain. However, 
prominent peaks indicative of alkenyl chains (Han and Gross, 
1996; Hsu and Turk, 2007) were absent in the earlier MS2 
analysis, thereby excluding this structural feature. The presence 
of a reproducible, low-intensity hexadecyl-carbocation at m/z 
225 in the MS2 spectra of the protonated molecule further 
supported the presence of an alkyl chain (Fig. 2 F). Together, 
the MS data defined the lipid antigen eluted at minute 17 as a 
lyso-glycero-methyl hydrogen phosphate with an ether-bonded 
C16 alkyl chain (1-O-hexadecyl-sn-glycero-3-phosphoric acid 
methyl ester, or methyl-lysophosphatidic acid [LPA; mLPA]; 
Fig. 2 H). High-resolution MS analysis supported this conclu-
sion by revealing a protonated molecular mass of 411.2872 D, 
compatible with the theoretical mass of the proposed molecule 
to within 0.5 parts per million (ppm) error (not depicted).
To confirm the proposed structure of the novel lipid, full 
assignment and structural elucidation of the compound were 
undertaken using one- and two-dimensional nuclear mag-
netic resonance (NMR) spectroscopy. A prominent signal was 
detected at 3.58 ppm in the proton NMR spectrum, corre-
sponding to the methoxy group on the phosphate portion of 
the novel lipid. The resonance reading for this phosphate 
moiety appeared as a doublet because of scalar coupling to the 
31P nucleus (3JHP = 10.9 Hz), but the doublet was resolved by 
decoupling (Fig. 2 I). Correlation spectroscopy (COSY) un-
raveled the complex pattern of the five glycerol protons (not 
depicted). We then applied a two-dimensional 13C-1H het-
eronuclear single quantum coherence spectroscopy correla-
tion (HSQC) to identify and assign all carbons and protons 
within the molecule (Fig. 2 I, right inset) and validated this 
assignment using a 31P-1H heteronuclear multiple bond cor-
relation (HMBC) to demonstrate the interaction of the phos-
phorus atom with the methoxy group and the H3 protons 
(not depicted). In support of these data, we prepared synthetic 
mLPA analogues that showed identical chemical shifts in the 
are activated in the absence of exogenous antigens, suggesting 
that they target cells expressing endogenous molecules pre-
sented by CD1c. Because CD1c is exclusively expressed on 
hematopoietic cells, we initially evaluated the capacity of dif-
ferent tumor cell lines of hematopoietic origin to activate 
CD1c autoreactive T lymphocytes. Two CD1c self-reactive 
T cell clones isolated from separate donors were stimulated 
with CD1c gene-transfected C1R cells (C1R-CD1c, repre-
sentative of Epstein-Barr virus–transformed lymphoblastoid 
cells) and THP1 cells (THP1-CD1c, representative of acute 
myeloid leukemia [AML]) and with four other cell lines that 
naturally expressed CD1c: CCRF-SB (a B cell acute lym-
phoblastic leukemia [B-ALL]), MOLT-4 and Jurkat (estab-
lished from T cell acute lymphoblastic leukemia [T-ALL]), 
and P3HR1 (a Burkitt’s lymphoma; Fig. 1 A). All six tumor 
cell lines induced T cell production of GM-CSF (Fig. 1 B) 
and IFN- (not depicted) in a CD1c-dependent manner, as 
indicated by full inhibition of target recognition with block-
ing anti-CD1c mAbs (Fig. 1 C). Hence, CD1c self-reactive 
T cells were stimulated by a broad range of hematological 
malignancies, raising the question as to which type of com-
mon self-lipid antigens stimulate these cells.
To identify the common lipid antigens, we used com-
bined biochemical approaches in conjunction with T cell ac-
tivation assays. Total lipids were extracted from the THP1 cell 
line, which most efficiently stimulated both CD1c-restricted 
T cell clones (Fig. 1 C). Separation of the total lipid mixture 
based on polarity and charge (Facciotti et al., 2012) revealed 
only one lipid fraction (G) that was capable of supporting the 
dose-dependent activation of self-reactive T cells by fixed 
CD1c+ APCs (Fig. 1 D). Fraction G also stimulated T cells 
when presented by plastic-bound recombinant soluble CD1c 
(sCD1c), whereas anti-CD1c mAb inhibited T cell activation 
in these assays (Fig. 1 E, left and middle). Control antigen sul-
fatide (Shamshiev et al., 2002) failed to stimulate T cells in 
these experiments, and an irrelevant CD1c-restricted T cell 
clone (specific for Mycobacterium tuberculosis lipids) did not re-
spond to fraction G, thus confirming the antigen specificity of 
the response (Fig. 1 E, right).
HPLC purification of the lipids in fraction G (Fig. 2 A) 
indicated that the lipids eluted at minutes 17, 18, and 19.5 
were capable of stimulating CD1c self-reactive T cells (Fig. 2 B). 
Liquid chromatography (LC)–tandem mass spectrometry (MS 
[LC-MS-MS]) was then used to reanalyze the lipids obtained 
at min 17 to better determine the structure of the tumor- 
associated lipid antigens. A single lipid was eluted at min 17 
(Fig. 2 C), and this compound exhibited a mass/charge (m/z) 
value of 409 in negative ion mode (Fig. 2 D). Because this 
mass did not match any known lipids, a detailed biochemical 
investigation was performed to identify the novel structure. 
Tandem MS (MS2) fragmentation of the novel compound 
yielded an ion of m/z 377 (Fig. 2 E), corresponding to the 
loss of methanol (32 D). The detection of an additional ion of 
m/z 167 in the low-mass region of the MS2 spectra indicated 
the presence of a phosphate moiety (signature ion m/z 153; 
Pulfer and Murphy, 2003) and an associated methyl group 
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between 0.5 and 2 µg/ml (Fig. 3 A). Two anti-CD1c mAbs 
completely inhibited the response (Fig. 3 B). The synthetic 
analogues also stimulated T cells when loaded onto plastic-
bound sCD1c molecules, thus confirming the recognition 
of the CD1c–mLPA complexes (Fig. 3 C). The same T cells 
were very weakly stimulated by other more common 
phospholipids (LPA, lysophosphatidylcholine [LPC], and 
lysophosphatidylethanolamine [LPE]) only at higher doses, 
>50 µg/ml, suggesting high specificity for mLPA (not depicted). 
Two additional CD1c self-reactive T cell clones isolated from 
a further two healthy donors (Fig. 3 D) and bearing different 
TCR / chains were also capable of recognizing the syn-
thetic analogues (Fig. 3 E), indicating that T cells specific for 
the novel lipids are present in healthy individuals. Collectively, 
these data identified the previously unknown self-lipid anti-
gen mLPA as a potent agonist for CD1c-restricted human 
T cells.
1H, 13C, and 31P spectra and recorded spectra from 1H-1H nu-
clear Overhauser effect spectroscopy (NOESY) and long-range 
13C-1H HMBC that were consistent with the postulated struc-
ture (not depicted).
A similar structure was also identified in the second active 
subfraction of THP1 lipid extract collected at min 18 (Fig. 2 B). 
Analysis of this molecule revealed a second lyso-glycero-methyl 
hydrogen phosphate that contained an ether-bonded C18-
alkyl chain (not depicted), which was longer than the C16 
alkyl chain present in the compound eluted at minute 17. 
Indeed, we characterized the stimulatory compound col-
lected at minute 18 as a C18 mLPA (not depicted).
We next used synthetic analogues of the naturally occur-
ring molecules (identical mass spectra and NMR behavior; 
not depicted) to test the antigenic potency of the novel lipids. 
The synthetic compounds very efficiently activated T cells 
when presented by CD1c+ APCs with potency ranging 
Figure 2. Identification of mLPA as a 
CD1c-restricted T cell antigen. (A) LC-MS 
total ion profile of fraction G derived from 
aqueous extract. (B) Activation of DN4.99  
T cells by fixed THP1-CD1c cells in the presence 
of HPLC-MS lipid subfractions (minutes 13–21) 
derived from fraction G. GM-CSF levels are 
expressed as fold change over background. 
Error bars represent SD. **, P < 0.01, deter-
mined by two-tailed Student’s t test. Data are 
representative of three independent experi-
ments. (C) Profile of LC-MS rechromatography 
of the active subfraction collected at 17 min. 
(D) Mass spectrum of the compound eluted at 
18.1 min, showing a single molecular species 
with m/z 409 in negative ion mode. (E) MS2 
spectrum of ion m/z 409. (F) MS2 spectrum of 
ion m/z 411 from fraction G as analyzed in 
positive mode. The presence of a methylated 
phosphate head group was confirmed by the 
detection of a major peak at m/z 299 (caused 
by the loss of 112 D from parent ion m/z 411) 
and presence of ions at m/z 187 and 169. A low 
intensity ion at m/z 225 was attributable to a 
hexadecyl-carbocation, which supported the 
existence of a C16 alkyl chain (as predicted  
by the negative mode analysis). (G) MS2  
spectrum of the unmodified LPA 1-O-9-(Z)- 
octadecenyl-sn-glycero-3-phosphate. The 
spectrum showed signature ions for a phos-
phate head at m/z 155 and 173. These ions 
were shifted to m/z 169 and 187 in the spec-
trum presented in F because of the presence of 
an additional methyl group in the polar head. 
(H) MS3 spectrum of ion m/z 377 and structure 
and fragmentation pattern of C16 mLPA. (I) Part 
of the 1H-NMR profile of the fraction collected 
at 17 min either without (bottom) or with (top) 
broadband decoupling on the 31P channel. 
Sections of the 13C-1H HSQC spectrum showing 
the relevant cross peaks for the assignment of 
mLPA (right).
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Differential recognition of primary leukemia blasts  
and healthy hematopoietic cells by mLPA-specific T cells
Because CD1c is expressed by a large proportion of acute 
leukemia blasts, we studied whether mLPA-specific T cells 
also recognize primary leukemia cells in a CD1c-dependent 
manner. Primary CD1c+ AML blasts freshly isolated from 
three different patients (Fig. 4 D) induced IFN- release by 
two mLPA-specific T cell clones, and their recognition was 
blocked by anti-CD1c mAbs (Fig. 4 E).
We next assessed whether mLPA-specific T cells recog-
nized cancer as well as normal CD1c+ cells. Initially, we ex-
amined the myeloid compartment. The selected AML blasts 
expressed lower levels of CD1c than normal circulating 
monocytes and DCs (cDCs; Fig. 5, A and B); nevertheless, 
they elicited higher levels of T cell activation than normal 
monocytes (Fig. 5 D) and similar to that of cDCs (Fig. 5 E), 
suggesting that AML blasts act as potent stimulatory cells. 
In vitro–differentiated monocyte-derived DCs (Mo-DCs) 
displayed high expression of CD1c (Fig. 5 B) and also exhib-
ited strong T cell stimulatory activity (Fig. 5 E). The recogni-
tion of all four cell types was fully inhibited by anti-CD1c mAbs 
(Fig. 5, D and E).
Next, we determined CD1c-restricted T cell recognition 
of transformed and normal B cells. Primary CD1c+ B-ALL 
blasts and healthy B cells displayed comparable CD1c expres-
sion levels (Fig. 5 C), yet the leukemic cells induced markedly 
higher production of IFN- by mLPA-reactive T cell clones 
Primary leukemia blasts express CD1 molecules
Having identified a novel self-lipid antigen that was pre-
sented by CD1c in leukemia cell lines, we next investigated 
the frequency of CD1c expression by leukemia blasts in pa-
tients. Peripheral blood and bone marrow samples obtained 
from AML, B-ALL, and T-ALL patients (Tables S1 and S2) 
were analyzed for the expression of different CD1 isoforms. 
Malignant cells were identified according to specific leuke-
mia-associated cellular phenotypes (Fig. 4). All leukemia 
blasts expressed CD1 molecules, although at different levels 
in different patients (Table 1 and Fig. 4). AML blasts from 
pediatric patients expressed CD1b (45% of patients) and 
CD1c (45%) but lacked CD1a and CD1d (Table 1). Pediat-
ric B-ALL blasts expressed CD1b (22%) and CD1c (26%) 
but rarely expressed either CD1a (4%) or CD1d (4%; Table 1 
and Fig. 4 A). Pediatric T-ALL blasts expressed CD1a (75%), 
CD1b (75%), and CD1d (50%) but displayed CD1c at much 
lower frequency (12%; Table 1 and Fig. 4 B). In adult pa-
tients, AML blasts expressed CD1b (54%), CD1c (51%), and 
CD1d (24%) but little CD1a (3%; Table 1 and Fig. 4 C). 
B-ALL blasts expressed CD1c (71%) and CD1d (29%), 
whereas CD1a and CD1b were undetectable (Table 1 and 
Fig. 4 A). CD1 molecules are thus frequently present on 
leukemia blasts. The expression of CD1 molecules was not 
associated with disease risk or particular clinical, cytoge-
netic, and molecular prognostic features (Tables S1 and S2; 
Döhner et al., 2010; Pui et al., 2011).
Figure 3. mLPA-specific T cells recog-
nize synthetic mLPA analogues. (A) T cell 
clones DN4.99 (left and middle) and K34A27f 
(right) were stimulated with synthetic C16 
mLPA presented by purified primary B cells. 
(B) DN4.99 and K34A27f T cells were stimu-
lated with purified primary B cells unloaded 
(no Ag) or loaded with 10 µg/ml C16 mLPA 
in the presence or not (ctrl) of two different 
anti-CD1c mAbs (F10/A213.1 or M241). (C) The 
same T cells were either cultured alone  
(T cells) or stimulated with plastic-bound 
sCD1c molecules loaded with control lipid 
(sulfatide) or synthetic mLPA (C16 or C18). 
(D) Recognition of C1R-CD1c but not C1R 
WT by CD1c self-reactive T cell clones 
DN4.99, DN16.3.6, and DN11.1.3, each ob-
tained from a different donor. The CD1c-
restricted M. tuberculosis–specific DL15A31  
T cell clone was used as a negative control 
for irrelevant specificity. (E) Activation of  
T cell clones DN4.99 (left), DN16.3.6 (middle), 
and DN11.1.3 (right) in the presence of puri-
fied primary B cells and synthetic C16 or C18 
mLPA (or without antigen, no Ag). T cell acti-
vation was evaluated by measurement of 
IFN- and/or GM-CSF release, expressed as 
mean ± SD. Results are representative of at 
least three independent experiments.  
*, P < 0.05; **, P < 0.01; ***, P < 0.001, deter-
mined by two-tailed Student’s t test.
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bacterial-derived lipids to specific CD1c-restricted T cell 
clones (Fig. 5, G and H), thus ruling out the possibility of an 
impaired lipid antigen presentation capacity of these cells. 
(Fig. 5 F). Also in this case, anti-CD1c mAbs completely 
blocked the recognition of B-ALL (Fig. 5 F). Normal B cells 
were able to present exogenously loaded synthetic mLPA or 
Figure 4. Primary leukemia blasts express CD1 molecules and stimulate mLPA-specific T cells. (A) CD1 expression by primary B-ALL blasts 
from a pediatric patient (p-BALL-08) and an adult patient (a-BALL-02). (B) CD1 expression by primary T-ALL blasts from two pediatric patients  
(p-TALL-04 and p-TALL-05). (C) CD1 expression by primary AML blasts from two adult patients (a-AML-18 and a-AML-28). Gating strategies to identify 
the patient-specific leukemia phenotypes are shown in the top panels. White histograms indicate specific staining of the gated populations with CD1-
specific mAbs, and gray histograms indicate the negative isotype-matched control staining (bottom). (D) CD1c expression by primary AML blasts from 
three adult patients (a-AML-02, a-AML-03, and a-AML-04). (E) Specific recognition of the same primary AML blasts by T cell clones DN4.99 (left) and 
K34A27f (right) at a 1:10 E/T ratio, in the presence of irrelevant mAb (ctrl) or anti-CD1c blocking mAbs (-CD1c). T cell activation was assessed by 
measuring IFN- release and was repeated twice with frozen aliquots of each leukemia sample. Data are expressed as mean ± SD. *, P < 0.05;  
**, P < 0.01; ***, P < 0.001, determined by two-tailed Student’s t test.
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kill acute leukemia primary cells and cell lines but efficiently 
killed M. tuberculosis–infected target cells (not depicted).
In a second type of experiment, the capacity of mLPA-
specific T cells to control leukemia cells in vivo was investi-
gated. The transfer of mLPA-specific T cells delayed the growth 
of CD1c+ MOLT-4 acute leukemia cells grafted into immuno-
deficient nonobese diabetic (NOD)/scid mice (Fig. 7 A), 
which displayed significantly increased survival compared 
with control groups that received either T cells with irrelevant 
specificity (CD1c-restricted and M. tuberculosis–specific) or 
vehicle alone (Fig. 7 B). MOLT-4 cells were used because 
they express CD1c (Figs. 1 A and 6 A), contain high amounts 
of mLPA (Fig. 5 I), and efficiently graft in these immuno-
compromised animals (not depicted). The two transferred T cell 
clones displayed a similar persistence in vivo. They both de-
clined from a mean of 10% of the mouse PBMCs on day 1 
after transfer to undetectable levels on day 7. The adoptive 
transfer of the same mLPA-specific T cell clone also signifi-
cantly delayed the progression of primary CD1c+ AML blasts, 
purified from the peripheral blood of a patient and trans-
ferred into immunocompromised NOD/scid/common  
chain/ (NSG) mice (Fig. 7 C). In all the mice, MOLT-4 cells 
retained CD1c expression upon progression, whereas the pri-
mary AML blasts reduced CD1c expression at week 5 after 
transfer independently of the transfer of mLPA-specific 
T cells (not depicted). Collectively, these findings indicate that 
(a) the long-term control of leukemia by the mLPA-specific 
T cells is probably ascribed to killing functions exerted in the 
first week after adoptive transfer, (b) progression of both leu-
kemias was not linked to CD1c down-regulation as escape 
mechanisms, and (c) the maintenance of CD1c gene expres-
sion in primary AML blasts transferred in NSG mice de-
pended on specific environmental cues.
Collectively, these experiments underscored the capac-
ity of mLPA-specific T cells to limit leukemia progression 
in vivo, suggesting the possibility to harness these T cells for the 
adoptive immunotherapy of CD1c+ acute leukemia. To di-
rectly assess this possibility, we generated primary T cell lines 
endowed with CD1c self-reactivity by transducing PBMCs 
from healthy donors with a lentivirus expressing the TCR  
and  chains of a CD1c self-reactive mLPA-specific T cell 
clone (Fig. 7 D). Only the T cells displaying surface expression 
of the transduced TCR chains, and not the untransduced ones 
sorted from the same cell line (Fig. 7 E), recognized a CD1c-
expressing tumor cell line (Fig. 7 F). Anti-CD1c mAbs inhib-
ited recognition. These results indicated that mLPA-specific 
T cells may be generated and expanded for adoptive immuno-
therapy of acute leukemia.
Absence of CD1c expression in hematopoietic precursors 
and in nonhematopoietic tissues of healthy individuals
We finally investigated the expression of CD1c in hematopoi-
etic precursors and other not lymphoid solid tissues to determine 
whether they might be targets of mLPA-specific CD1c- 
restricted T cells. CD1c was undetectable by flow cytometry 
on relevant subsets of primary CD34+ HSCs and immature 
Collectively, these data indicated that mLPA-specific T cells 
recognize malignant cells more efficiently than normal primary 
hematopoietic cells.
Accumulation of mLPA in leukemic cells
We next quantified the amount of mLPA present in primary 
leukemia blasts and in acute leukemia cell lines. C16 mLPA 
was detected in all the primary leukemia samples tested (11 
AML and 5 B-ALL; range 0.58–35.22 ng/106 cells) in THP1 
and MOLT-4 cells (31.68 and 8.76 ng/106 cells, respectively; 
Fig. 5 I), thereby confirming that mLPA is commonly present 
in leukemic cells. C16 mLPA was also detected in large 
amounts in Mo-DCs (range 0.35–2.96 ng/106 cells), in agree-
ment with the stimulatory capacity of these cells (Fig. 5 E). 
Very low quantities of C16 mLPA were detected in normal 
circulating monocytes and B cells (range 0.03–0.07 and 0.01–
0.05 ng/106 cells, respectively; Fig. 5 I), in agreement with 
their poor T cell stimulatory activity (Fig. 5, D and F). These 
data suggested that mLPA accumulates in leukemia cells but is 
poorly present in normal hematopoietic cells, with the ex-
ception of in vitro–differentiated Mo-DCs.
mLPA-reactive T cells kill leukemic cells  
and limit tumor growth in vivo
To assess the relevance of leukemia recognition by mLPA-
specific T cells, we investigated the ability of these cells to re-
strict the growth of CD1c+ acute leukemia cells in different 
settings. T cell clones specific for mLPA were capable of kill-
ing CD1c+ primary AML and B-ALL blasts and acute leuke-
mia cell lines in a CD1c-dependent manner in vitro (Fig. 6, 
A–C). mLPA-specific T cell clones did not kill normal B cells, 
unlike leukemic B cells, whereas they killed normal mono-
cytes, albeit less efficiently than AML blasts (Fig. 6 B).
Remarkably, the mLPA-specific T cells efficiently killed the 
CD34+ CD117+ myeloid leukemia blasts identified by the ex-
pression of the specific leukemia-associated immune phenotype 
(LAIP; Vidriales et al., 2003), which are responsible for the min-
imal residual disease in treated patients (Fig. 6 D). The control 
M. tuberculosis–specific CD1c-restricted T cell clone failed to 
Table 1. CD1 expression by primary leukemia blasts
Malignancy Number Patients with CD1-expressing blasts
CD1a CD1b CD1c CD1d
% % % %
Pediatric patients
AML 9 0 45 45 0
B-ALL 23 4 22 26 4
T-ALL 8 75 75 12 50
Adult patients
AML 33 3 54 51 24
B-ALL 7 0 0 71 29
Data refer to circulating blasts. Similar CD1 expression frequencies were observed in 
bone marrow biopsy samples.
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by mLPA, which may represent promising novel targets for 
immunotherapy in human leukemia. We readily detected 
mLPA in primary human leukemia cells and confirmed that 
this antigen is potently stimulatory for CD1c-restricted T cell 
clones, which restrained leukemia progression in mice xeno-
grafted with human tumor cells.
mLPA is an unusual lysoglycerophosphate molecule never 
described before. It includes at least two different alkyl chains 
and displays two prominent structural features. The first is the 
presence of a methyl group on the phosphate moiety, which 
is shared in common with lysophosphomethanol (LPM). 
Both LPM and mLPA are methylated LPAs, but where LPM 
incorporates an sn-1 ester-bonded alkyl chain, mLPA instead 
features an ether bond. LPM is generated by autotaxin-medi-
ated cleavage of LPC and accumulates in mouse cells to promote 
the proliferation and migration of tumors (Endo et al., 2009). 
precursors contained in cord blood (Fig. 8 A), suggesting that 
HSC recognition by CD1c self-reactive T cells is unlikely to 
occur in healthy individuals. CD1c mRNA was also almost 
undetectable in several parenchymatous organs and nonlym-
phoid tissues (Fig. 8 B), confirming that tissues do not express 
CD1c (Porcelli and Modlin, 1999; Brigl and Brenner, 2004). 
These results suggested that hematopoietic cell precursors as 
well as solid organs are unlikely to be targeted by mLPA-specific 
CD1c-restricted T cells.
DISCUSSION
The tumor-associated antigens identified so far consist pri-
marily of proteins that stimulate specific T cells only when 
processed into small peptides presented by HLA molecules 
(Speiser and Romero, 2010; Seremet et al., 2011). In this study, 
we identified a unique class of lipid self-antigens, exemplified 
Figure 5. Differential recognition of 
malignant and healthy hematopoietic cells 
by mLPA-reactive T cells. (A–C) Expression 
of CD1c by healthy donor-derived primary 
monocytes and primary AML blasts (A), pri-
mary DCs purified from circulating mono-
nuclear cells (cDCs) and Mo-DCs (B), and B cells 
from healthy donors and primary B-ALL  
blasts (C). (D–F) The same cell types were used 
to stimulate DN4.99 T cells in the presence of 
anti-CD1c mAbs (-CD1c) or isotype-matched 
control mAbs (ctrl). IFN- release by T cells 
was measured and expressed as mean ± SD. 
(G) Normal B cells efficiently presented M. 
tuberculosis lipid antigen (MTB sonicate) to 
CD1c-restricted M. tuberculosis–specific  
T cells (DL15A31). C1R-CD1c lymphoblastoid 
cells were used as control. T cell activation 
was assessed by measuring release of GM-
CSF, expressed as mean ± SD. (H) Normal  
B cells efficiently presented C16 mLPA to CD1c 
self-reactive T cells (DN4.99). T cell activation 
was evaluated by measuring release of IFN-, 
expressed as mean ± SD. (A–H) Results are 
representative of three (A–G) and four (H) 
independent experiments. *, P < 0.05;  
**, P < 0.01; ***, P < 0.001, two-tailed Student’s 
t test. (I) C16 mLPA content in normal primary 
circulating monocytes (n = 3) and B cells from 
healthy donors (n = 3), in vitro–differentiated 
Mo-DCs (n = 4), primary circulating B-ALL 
and AML blasts (acute leukemia, n = 5 and  
n = 11, respectively), AML cell line THP1, and 
T-ALL cell line MOLT-4. In primary acute leuke-
mia samples the percentage of blasts ranged 
between 75 and 97%. The mLPA concentra-
tion value of each sample represents the 
mean value of two to three independent de-
terminations performed with the same sam-
ple. Horizontal bars represent the mean values 
of the primary samples. *, P < 0.05; **, P < 
0.01; ns, not statistically different, two-tailed 
Student’s t test.
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Figure 6. mLPA-specific T cells kill CD1c+ acute leukemia cells. (A) CD1c expression by the indicated primary normal monocytes, primary 
AML blasts, and leukemia cell lines. (B) Killing of 51Cr-labeled primary AML and B-ALL blasts and normal purified monocytes and B cells. Cell tar-
gets were cultured with mLPA-specific T cells (K34A27f) at increasing E/T ratio in the presence of isotype control (ctrl) or CD1c blocking mAbs  
(-CD1c). 51Cr-labeled THP1-CD1c cells were used as positive control. Data are representative of two independent experiments. Two-tailed paired 
Student’s t test was used to compare the curves: *, P < 0.05; **, P < 0.01; ***, P < 0.001. (C) The indicated cell targets were cultured with mLPA-
specific T cells (K34A27f) at the indicated E/T ratios in the presence of isotype control (ctrl) or CD1c blocking mAbs (-CD1c). The percentages of 
apoptotic blasts were determined by flow cytometry using Annexin V and DAPI staining. Columns indicate mean ± SD and are representative of 
two and three independent experiments with primary AML blasts and leukemia cell lines, respectively. *, P < 0.05; **, P < 0.01, determined by two-
tailed Student’s t test. (D) FACS analysis of apoptotic primary AML blasts (a-AML-18) upon co-culture with mLPA-specific T cells (K34A27f) in the 
presence of isotype control mAbs (IgG1 isotype ctrl, middle) or anti-CD1c mAbs (-CD1c, bottom). Spontaneous apoptosis of AML blasts in the 
absence of T cells is also shown (top). Leukemic cells responsible for the minimal residual disease in treated patients were identified by coexpres-
sion of CD34 and CD117 according to their specific LAIP (left). Apoptotic cells were defined by combined staining with DAPI and Annexin V (right). 
Data are representative of two independent experiments.
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hematopoietic lineages. We also measured high levels of mLPA 
in Mo-DCs, induced upon culturing with the inflammatory cy-
tokines GM-CSF and IL-4, whereas it was detected at trace 
levels in normal circulating monocytes and B cells, consistent 
with their different stimulatory activity for T cells. In this re-
spect, the cellular distribution of mLPA resembles that of 
other tumor-associated antigens that accumulate in tumor 
cells but are also present in healthy cells (Jäger et al., 2001; 
Boon et al., 2006). LPC, another lysophosphoglycerolipid, 
was also found to accumulate in the plasma in myeloma pa-
tients and to stimulate CD1d-restricted type II NKT cells. 
These latter cells were proposed to regulate chronic inflam-
mation in cancer patients (Chang et al., 2008). These data 
support a similar link between oncogenetic stress, lysophos-
pholipid biosynthesis, and CD1-restricted T cell responses.
Lipolytic release and remodeling of free fatty acids are 
associated with metabolic changes in tumor cells (Hsu and 
Sabatini, 2008;  Vander Heiden et al., 2009) and could con-
tribute to mLPA accumulation in cancers. Tumor cells often 
express increased levels of monoacylglycerol lipase, an enzyme 
which also generates lysophospholipids (Nomura et al., 2010) 
and induces accumulation of LPA. LPA is structurally similar 
to mLPA and can rescue cancer cells from migration defects 
The close structural similarity of mLPA and LPM suggests 
that these molecules could exert similar biological effects in 
tumor cells.
The second prominent structural feature of mLPA is the 
ether bond that links the alkyl chain to glycerol, which is a 
peroxisomal hallmark of ether-bonded lipid synthesis (Wanders 
et al., 2010). Peroxisome numbers increase in tumor cells 
(Cha et al., 2009) and increased  oxidation of fatty acids in 
peroxisomes is critical for tumor cell growth (Schrader and 
Fahimi, 2006). Because augmented peroxisome frequency 
and activity are characteristic of altered tumor cell metabolism, 
it is conceivable that the immune system recognizes accumu-
lated peroxisome-derived lipids as tumor antigens. Indeed, a 
recent study has reported that a peroxisome-derived lipid anti-
gen promotes thymic expansion and peripheral homeostasis 
of natural killer T cells (Facciotti et al., 2012). Peroxisomes 
thus represent an important source of lipids that can stimulate 
specific T cell responses in immunoregulation and tumor sur-
veillance and may therefore also contribute to host protection 
against leukemias.
A key finding of our study was that mLPA can be de-
tected in large amounts in different types of primary leu-
kemic blasts and in established tumor cell lines of different 
Figure 7. mLPA-specific T cells are promising 
tools for T cell adoptive immunotherapy of 
CD1c+ acute leukemia. (A) Percentage of circulat-
ing MOLT-4 cells at different time points in mice 
inoculated with CD1c-restricted T cell clones spe-
cific for mLPA (K34A27f) or M. tuberculosis 
(DL15A31) or with saline only (vehicle). Horizontal 
bars represent the mean values. *, P < 0.05; ns, not 
significant, two-tailed Student’s t test. (B) Survival 
of mice that received either T cells or vehicle alone. 
Data show cumulative results from three indepen-
dent experiments including five mice per group. 
Mice that received mLPA-specific T cells showed 
increased survival. **, P < 0.01, Mantel-Cox test.  
(C) Progression of human primary CD1c+ AML blasts 
in NSG mice that received mLPA-specific K34A27f  
T cells (n = 5) or vehicle only (n = 5). The percentage 
of AML blasts was monitored by flow cytometry in 
PBMCs at the indicated times. Bars indicate mean ± 
SD. Results are representative of two independent 
experiments. ***, P < 0.001, nonparametric Student’s 
t test. (D) Map of the bicistronic lentivirus vector 
pHR-SINEGFP carrying the chimeric TCR V-(D)-J 
segments from the mLPA-specific T cell clone 
DN4.99, fused with the mouse TCR C or C cDNAs. 
Both chains are expressed from the internal spleen 
focus forming virus (SSFV) promoter. (E) Generation 
of mLPA-specific T cell lines in vitro upon transduc-
tion of polyclonal T cells with the lentivirus de-
scribed in D. TCR expression by transduced (TrT, blue 
lines) and untransduced (UTrT, red lines) T cells at days 0 and 15 and after sorting. TCR expression was detected using mouse C-specific (mTCR) 
mAbs. Data are representative of three experiments. (F) Recognition C1R-CD1c lymphoblastoid cells by T cells transduced with the DN4.99 TCR (TrT) 
but not by untransduced ones (UTrT). T cells were cultured without (no APCs) or with C1R-CD1c cells in the presence (-CD1c) or absence (ctrl) of 
anti-CD1c blocking mAbs. Bars indicate mean ± SD of IFN- production of triplicate cultures. Results are representative of three experiments.  
*, P < 0.05; **, P < 0.01; ns, not statistically different, two-tailed Student’s t test.
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strategies that selectively target malignant cells without in-
ducing GVHD hold promise for the control of tumor recur-
rence after HSCT in acute leukemia (Kolb, 2008). Targeting 
CD1c molecules and tumor-associated lipid antigens for im-
munotherapy might ideally integrate strategies that target 
protein antigens with remarkable advantages. Unlike peptide 
antigens (Matsushita et al., 2012), lipid antigens do not un-
dergo structural changes when subject to the strong selective 
pressure of specific immune responses. Alterations of entire 
lipid biosynthetic pathways are often incompatible with cell 
survival, thus making loss of lipid antigens in tumor cells an 
unlikely mechanism of cancer immune evasion. Furthermore, 
the nonpolymorphic nature of CD1c and high frequency of 
CD1c+ leukemia (50%) might make adoptive immunother-
apy with mLPA-specific T cells applicable in a large number 
of patients. The adoptive transfer of mLPA-specific T cells 
might complement immunotherapy with HLA-restricted 
T cells in HLA-haploidentical transplants, in which the leu-
kemia blasts relapse and escape immune recognition after loss 
of HLA (Vago et al., 2009).
We showed that mLPA-specific T cells able to recognize 
leukemia blasts in a CD1c-dependent manner could be gen-
erated in vitro upon transduction of mLPA-specific TCR 
genes. This strategy might represent a relatively safe approach 
for immunotherapy of acute leukemia. Indeed, allogeneic 
T cells from stem cell donors might be transduced and their 
potential alloreactivity might be prevented by editing the endog-
enous TCR genes (Canderan et al., 2010; Provasi et al., 2012). 
and promote oncogenesis via activation of G protein–coupled 
receptors (Dorsam and Gutkind, 2007). LPA also promotes 
cytoskeletal reorganization, chemotaxis, and cell growth (Mills 
and Moolenaar, 2003), as well as inducing CXCL1 secretion, 
tumor progression, vascular remodeling, and reversal of cell 
differentiation (van Meeteren and Moolenaar, 2007). mLPA 
may confer similar advantages on rapidly growing cells, which 
could explain the accumulation of this lipid in tumors.
Our findings raise important questions concerning the 
physiological role of mLPA-specific T cells in healthy individ-
uals versus cancer patients. This particular antigen specificity 
might “jump-start” immune responses by promoting rapid DC 
maturation and accelerating the expansion of antigen-specific 
B and T cells (Vincent et al., 2002; Cerundolo et al., 2009). 
Recognition of accumulating mLPA might represent a mecha-
nism by which the host immune system recognizes self-lipid 
molecules as markers of cellular stress (De Libero et al., 2005). 
In addition, mLPA-specific T cells may participate in tumor 
immune surveillance, using their cytolytic capacity to eliminate 
potentially tumorigenic cells undergoing uncontrolled prolif-
eration. Further investigation is warranted to unravel whether 
in patients the extent of the leukemia burden might have re-
duced T cells involved in leukemia immune surveillance.
The value of mLPA-specific T cells as novel immunother-
apeutic tools is supported by their protective effect in a mouse 
xenograft model of human leukemia. These experiments sug-
gested that mLPA-specific T cells may target leukemic cells 
in human patients in vivo. Adoptive T cell immunotherapy 
Figure 8. CD1c expression pattern in human he-
matopoietic precursors and healthy organs. (A) Nor-
mal hematopoietic precursors lack CD1c expression. 
Cord blood (CB) cells from healthy donors were stained 
with the indicated mAbs (CD34-FITC, anti–CD45-
APCCy7, CD38-PECy7, CD45RA-PB, CD90-APC, and 
anti–CD1c-PE). The boxes represent the gates used to 
identify HSCs, multipotent progenitors (MPPs), and 
multilymphoid progenitors (MLPs), according to Doula-
tov et al. (2012). Representative dot plots from at least 
three independent experiments are shown. (B) CD1c 
mRNA expression in human tissues. RT-qPCR for CD1c 
expression was performed on cDNAs from human tis-
sues contained in the TissueScan Real-Time Human 
Major Tissue Panels II (OriGene), according to the man-
ufacturer’s instructions. We added two custom cDNAs, 
produced by us from THP1-CD1c and THP1 WT cell 
lines, as positive and negative controls for CD1c expres-
sion. The data obtained were normalized against a cali-
brator signal, provided by the level of CD1c cDNA 
detection in PBMCs. CD1c expression was detected  
in lymph nodes, spleen, and thymus, whereas it was 
almost undetectable in all of the other tissues.
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anti–CD11c-APC (clone B-ly6; BD). Samples were acquired on CyAn ADP 
(Dako) or FACSCanto (BD) flow cytometers. Cell sorting experiments were 
performed using a MoFlo sorter (Beckman Coulter). Dead cells were ex-
cluded on the basis of propidium iodide and DAPI staining. All data were an-
alyzed using FlowJo software (Tree Star). Relative fluorescent intensity (RFI) 
of CD1c expression on leukemia cells was calculated dividing the mean 
CD1c fluorescence intensity by the mean fluorescence intensity of the cor-
responding isotype control mAb.
T cell activation assays. T cell activation assays were performed by cocultur-
ing the indicated numbers of target cells (5 × 104/well unless otherwise indi-
cated) with T cells (5 × 104/well) in 200-µl volume in duplicate or triplicate 
cultures. In some experiments, mouse anti-CD1c (L161; Abcam) or mouse 
IgG1 isotype control mAbs were added and incubated for 30 min before the 
addition of T cells. Supernatants were collected after 24–48 h, and cytokines 
released by T cells (GM-CSF and/or IFN-) were measured by ELISA. In as-
says using fractionated lipids, THP1-CD1c cells (5 × 104/well) were fixed with 
0.05% glutaraldehyde for 20 s and used as APCs. Fold change in cytokine re-
lease was calculated using the following formula: GM-CSF release with lipid-
pulsed APC/GM-CSF release with unpulsed APC. In some experiments, 
normal B cells purified from PBMCs (5 × 104/well) were used as APCs with-
out prior fixation. APCs were pulsed with lipids for 4 h at the indicated dilu-
tions before addition of T cells. sCD1c plate-bound assays were performed 
using MaxiSorp plates (Thermo Fisher Scientific) coated with anti-BirA mAb 
(Nowbakht et al., 2005) to capture sCD1c and were then incubated with lipids 
for 6 h. The wells were extensive y washed before addition of T cells. Each 
stimulation was performed in triplicate. Killing assays were performed using 
target primary blasts or established leukemia cell lines (2 × 104 cells/ml) incu-
bated either alone or with T cells at different E/T ratios for 24 h, in the pres-
ence or absence of anti-CD1c mAb (L161). Killing of 51Cr-labeled targets was 
performed as described previously (Montagna et al., 2006). The mean sponta-
neous release ranged between 15 and 22% of total release. In the killing assays 
performed by flow cytometry, the target cells were stained with PE–Annexin 
V (BD) and DAPI (Sigma-Aldrich), according to published protocols (Jedema 
et al., 2004). Leukemia blasts were identified by their specific LAIPs and then 
assessed for apoptosis as follows: Annexin V+ DAPI+ = advanced apoptosis and 
Annexin V DAPI+ = necrosis. The percentage of apoptotic + necrotic cells in 
the absence of T cells (spontaneous apoptosis) was subtracted from the percent-
age of apoptotic + necrotic cells in the presence of T cells (induced apoptosis) 
to obtain the proportion of blasts killed by T cells.
T cell transduction with lentivirus encoding the mLPA-specific 
TCR genes. The generation of the bicistronic lentivirus vector pHR-
SINEGFP (provided by V. Cerundolo, University of Oxford, Oxford, Eng-
land, UK) encoding the chimeric TCR  and  genes from the mLPA-specific 
T cell clone DN4.99 was performed as described previously (Canderan et al., 
2010). To generate the chimeric TCR chains, the TRAV38-TRAJ44 and the 
TRBV28-TRBJ2-7 segments were fused with the mouse TRAC and TRBC 
cDNA, respectively, by PCR. T cells were purified form healthy donors and 
activated with anti-CD3/CD28 immunomagnetic beads (Invitrogen) in RPMI-
FCS complete medium supplemented with 100 U/ml hrIL-2 and 10 ng/ml 
IL-7 (R&D Systems). 2 d after activation, 4 × 105 T cells were infected in 500 µl 
complete medium at a multiplicity of infection of 5. After 15 d, transduced 
T cells were sorted for mouse TCR- expression. Both positive and negative 
cells were stimulated with anti-CD3/CD28 immunomagnetic beads and cy-
tokines and tested for antigen recognition after 10 d.
Production of purified sCD1c. Recombinant soluble human CD1c 
tagged with BirA peptide (sCD1c), was obtained and purified using tech-
niques similar to those previously described (Garcia-Alles et al., 2006). The 
following primers were used to PCR amplify the extracellular domain of 
human CD1c: forward XhoI, 5-CTCGAGGACATGCTGTTTCTGCAG-
TTTC-3; and reverse ClaI, 5-CCATCGATGGGGTTTCTCCAGTAG-
AGGA-3. sCD1c was purified from J558-transfected cell culture supernatants 
by affinity chromatography using anti-CD1c mAb (10C3; BD).
An issue that deserves careful evaluation is that mLPA-specific 
T cells killed normal monocytes in vitro. In the case of mLPA-
specific adoptive T cell therapy in the course of HSCT, this 
side effect might be tolerated by patients during the peri-
transplant period, when the control of minimal residual leu-
kemia is paramount. Importantly, the absence of CD1c in 
hematopoietic cell precursors and its almost undetectable 
expression in parenchymatous organs and nonlymphoid tis-
sues might prevent harmful reactions of transferred mLPA-
specific T cells. Transduced cells might also be engineered 
with suicide genes, currently used in the clinics (Ciceri et al., 
2009), to prevent or halt GVHD.
In conclusion, we have identified mLPA as a novel lipid 
antigen that potently activates CD1c-restricted human T cells. 
The broad expression of CD1 molecules by a large number of 
primary acute leukemias, combined with the wide distribution 
of mLPA in leukemias and the presence of mLPA-specific 
T cells in blood of healthy individuals, could provide new op-
portunities for cellular immunotherapy in human patients.
MATERIALS AND METHODS
Cells. The following human cell lines were obtained from the ATCC: C1R 
(Epstein-Barr virus–transformed B lymphoblastoid), THP1 (myelomonocytic 
leukemia), MOLT-4 and Jurkat (T-ALL), CCRF-SB (B-ALL), and P3HR1 
(Burkitt’s lymphoma). THP1-CD1c cells were generated by transfection of 
the human CD1c gene construct as previously described (Manolova et al., 
2003). Primers used for PCR amplification were as follows: forward XhoI, 
5-CTCGAGGACATGCTGTTTCTGCAGTTTC-3; and reverse NotI, 
5-GCGGCCGCTCACAGGATGTCCTGATATGAGC-3. C1R-CD1c 
cells were provided by S. Porcelli (Albert Einstein College of Medicine, 
Bronx, New York). Bone marrow and peripheral blood samples containing 
primary leukemia blasts were obtained after written informed consent from 
adult patients or from the parents of pediatric patients in accordance with the 
Declaration of Helsinki. The study was approved by the Institutional Review 
Boards of San Raffaele Scientific Institute, Milan, and Fondazione IRCCS 
Policlinico San Matteo, Pavia. Primary AML, T-ALL, and B-ALL leukemia 
samples were provided by Unità Trapianto Midollo Osseo (San Raffaele, 
Milan), Northern Italy Leukemia Group (Bergamo), and A. Wodnar-Filipowicz 
(University of Basel, Basel, Switzerland). T cell clones were generated and 
maintained in culture as previously described (Shamshiev et al., 1999; de Lalla 
et al., 2011). Normal monocytes and B cells were purified (>90% purity) 
from PBMCs obtained from healthy volunteers using anti-CD14 and anti-
CD19 immunomagnetic beads, respectively, according to the manufacturer’s 
instructions (Miltenyi Biotec). cDCs were enriched from PBMCs using 
human DC enrichment beads (Invitrogen), and the unbound fraction was 
sorted according to the expression of CD64 and CD11c. The resulting 
CD64+CD11c+ cDCs (>95% purity) uniformly expressed CD1c. Mo-DCs 
were differentiated in vitro from purified CD14+ monocytes in the presence 
of GM-CSF and IL-4 as described previously (Shamshiev et al., 1999).
Flow cytometry. CD1 expression was determined using mAbs anti–CD1a-
PE (clone HI149; BD), anti–CD1b-PE (clone 0249; Santa Cruz Biotechnol-
ogy, Inc.), anti–CD1c-PE (clone L161; Santa Cruz Biotechnology, Inc.), and 
anti–CD1d-PE (clone 42.1; BD). Leukemia blasts were identified using anti–
CD19-FITC or CD19-PerCPCy5.5 (both clone HIB19) and anti–CD14-
FITC (clone HCD14; all from BioLegend); anti–CD3-FITC (clone 
UCHT1), anti–CD45-APC (clone HI30), and anti–CD117-PerCpCy5.5 
(clone 2B8; all from BD); anti–CD7-PC5 (clone 8H8.1), anti–CD10-PC5 
(clone ALB1), anti–CD33-FITC or CD33-PC5 or anti–CD33-APC (all 
clone D3HL60-251), anti–CD34-FITC or CD34-PC5 or anti–CD34-APC 
(all clone 581), and anti–CD45-PC7 (clone J33; all from Beckman Coulter). 
cDCs were sorted using anti-CD64 FITC (clone 22; Beckman Coulter) and 
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mLPA was dissolved in 30 µl solvent, syringe-transferred to a 1.7-mm-
diameter NMR sample tube, and then sealed. The two-dimensional experi-
ments were recorded with 2,048 data points in the direct dimension, and 
increments in the indirect dimension numbering 1,024 (COSY and HSQC) 
or 256 (31P-HMBC), resulting in acquisition times of 285 (F2) and 142 ms 
(F1) for the COSY, 142 and 20.5 ms for the HSQC, and 142 and 10.5 ms for 
the 31P-HMBC. The COSY was performed with eight scans per increment, 
leading to a total experiment time of 3 h, 21 min; for the HSQC these pa-
rameters were 144 scans and 64 h, 17 min; and for the 31P-HMBC, eight 
scans and 59 min. A 31P decoupling 180° pulse was applied during the 13C 
evolution period of the sensitivity-enhanced Echo-Antiecho HSQC experi-
ment. The long-range delay in the 31P-HMBC was set to 62.5 ms. All other 
NMR investigations were routine experiments.
Human leukemia xenograft model. We generated a human leukemia xeno-
graft model in immune-compromised mice according to published protocols 
(Bondanza et al., 2006; Provasi et al., 2012). TM-1 anti–mouse IL-2R block-
ing mAb (clone TM-1; provided by K. Tanaka, Tokyo Metropolitan Institute of 
Medical Science, Tokyo, Japan) was injected i.p. 24 h before the start of the ex-
periment in 6–8-wk-old female NOD/scid mice (Charles River) to neutralize 
residual NK cell activity. On day 0, mice were conditioned by 175 cGy sub-
lethal irradiation and then immediately infused i.v. with 106 MOLT-4 cells en-
gineered to express EGFP via lentivirus transfer. After 48 h, the mice were 
divided into three groups (five animals/group) that received vehicle alone, 
mLPA-specific CD1c-restricted T cells (K34A27f), or M. tuberculosis–specific 
CD1c-restricted T cells (DL15A31; 107 cells/mouse). The proliferation of 
human leukemia cells in blood was monitored weekly by flow cytometry. 
MOLT-4 cells were identified as human-CD45/EGFP double-positive cells. 
Moribund mice were euthanized for ethical reasons. For experiments with 
primary human leukemia blasts, AML blasts were purified from the blood of an 
AML patient and injected i.v. (8 × 106/animal) into 14 NSG mice. 2 d later, 
1.5 × 107 K34A27f T cells were injected into half of the mice, and leukemia pro-
gression was monitored weekly by flow cytometry of PBMCs. The area under 
the curve describing the kinetic of AML expansion in peripheral blood was 
calculated for each mouse infused with K34A27f cells or with vehicle only and 
values derived from the two groups of animals compared. Animal experiments 
were approved by the Institutional Animal Care and Use Committee of the San 
Raffaele Scientific Institute (IACUC no. 370).
Statistical analyses. Cytokine assay data were analyzed using a two-tailed 
Student’s t test. Data describing the presence of leukemia cells in injected 
mice were analyzed with two-tailed nonparametric Student’s t test. Animal 
survival data were analyzed using log-rank (Mantel-Cox) test.
Online supplemental material. Tables S1 and S2 show the clinical char-
acteristics of pediatric and adult patients, respectively. Table S3 shows the C16 
and C17 mLPA MRM transitions. Online supplemental material is available 
at http://www.jem.org/cgi/content/full/jem.20140410/DC1.
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Lipid extraction and analysis. Total lipids were extracted from a dry pellet 
of 109 THP1 cells with water/methanol/chloroform (1:1:2 vol/vol/vol). The 
chloroform layer was collected, centrifuged, dried, and dissolved in chloro-
form/methanol (9:1 vol/vol). Highly polar lipids were extracted from the re-
maining aqueous phase using butanol (1 vol added) and then centrifuged, 
dried, and redissolved in chloroform/methanol (9:1 vol/vol). Both organic 
and aqueous extractions were separately loaded on an amino-propyl Sep-Pak 
cartridge (Waters Corporation), and lipids were fractionated into 10 fractions 
as previously described (Facciotti et al., 2012). No structural modifications 
were observed in a mixture of standard lipids subjected to the same experi-
mental procedures, thus excluding qualitative effects of the solvents and the 
amino-propyl cartridges on the eluted lipids. Subfractionation of fraction G was 
performed by HPLC using a reverse-phase C18 polar end-capped column 
(3-µm particle size, 3-mm ID, 125-mm length; MACHEREY-NAGEL) as 
previously described (Facciotti et al., 2012). LC-MS-MS was performed 
using a Rheos Allegro pump (Flux Instruments) and HTC PAL injector with 
a 20-µl loop (CTC Analytics AG). MSn were acquired using an LXQ ion trap 
mass spectrometer equipped with a heated electrospray ionization (ESI) 
source (Thermo Fisher Scientific) controlled by Xcalibur software (Thermo 
Fisher Scientific). Source conditions were as follows: spray voltage, 5 kV; cap-
illary voltage, 12 V; capillary temperature, 265°C; tube lens offset voltage, 100 V; 
and sheath gas flow rate, 15 U. Helium was used as the damping gas. CID 
spectra were acquired on an API 4000 LC-MS-MS system with a triple 
quadrupole analyzer (Applied Biosystems/MDS Sciex). Exact mass measure-
ments were performed with LTQ MS (Thermo Fisher Scientific). All lipid 
standards were purchased from Avanti Polar Lipids, Inc.
To quantify the amounts of C16 mLPA contained in leukemic and 
healthy cells, polar lipids were extracted with a one-step methanol-based 
method (Zhao and Xu, 2010). In brief, dry cell pellets were frozen in liquid 
nitrogen (5 min) and then kept on ice for 3 min and finally brought to room 
temperature in water for 2 min. Samples were vortexed (30 s), added to 50 µl 
water, vortexed for an additional 30 s, added to 450 µl methanol, vortexed 
again (30 s), and finally sonicated for 3 min. After centrifugation (10 min, 
10,000 g), the upper phase was collected and dried under the fume hood. Dry 
lipid extracts were resuspended in 30 µl methanol, and 5 µl was injected into 
the ultra-performance LC (UPLC) tandem MS (UPLC-MS-MS) for analy-
sis. UPLC was performed on a Waters ACQUITY UPLC system (Waters 
Corporation) using a 2.1 mm × 100 mm × 1.7 µm ACQUITY UPLC BEH 
C18 column with a flow rate of 0.20 ml/min. The column temperature was 
held at 30°C. The solvent system applied was mobile phase A (2 mM ammo-
nium formate in Milli-Q water) and mobile phase B (acetonitrile, HPLC 
grade) with a gradient starting at 70% A–30% B and ramping to 100% B over 
10 min. MS detection was performed using a Xevo TQS Tandem MS detec-
tor (Waters Corporation) equipped with an ESI source operating in negative 
ionization and multiple reaction monitoring (MRM) mode. The desolvation 
gas flow rate was set to 800 liter/h at a temperature of 350°C. The capillary 
voltage was set to 2,500 V. The precursor to product ion transitions (quantifi-
cation and target ions), dwell times, cone voltage, and collision energy for 
C16 mLPA and the internal standard C17 mLPA are listed in Table S3. Data 
were acquired and processed with MassLynx software version 4.1 (Waters 
Corporation) using peak area ratio for quantification. C16 and C17 mLPA 
molecules were synthesized in house.
NMR. mLPA spectra were recorded on an Avance III spectrometer (Bruker) 
operating at 14.1 Tesla and 298K. The spectrometer was equipped with a triple- 
resonance (1H, 13C, 31P), 1.7-mm micro probe head with a self-shielded 
z-gradient coil. All mLPA experiments were performed in sodium formate– 
buffered deuterated methanol (99.96% D; Cambridge Isotopes Laboratories). 
All synthetic samples were prepared in deuterated solvents (>99.8% D; Cam-
bridge Isotope Laboratories). The NMR experiments conducted on synthetic 
samples were performed using a DRX–600 MHz NMR spectrometer (equipped 
with a self-shielded z-axis pulsed field gradient dual-channel broadband in-
verse 5-mm probe head; Bruker). Chemical shifts were referenced to residual 
solvent peaks.
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